Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer

• US 20040228917A1
• Filed: 06/18/2004
• Published: 11/18/2004
• Est. Priority Date: 12/24/1991
• Status: Active Grant

• Current Assignee: Purdue Pharma L.P.
• Original Assignee: Purdue Pharma L.P.
• Inventors: Oshlack, Benjamin, Chasin, Mark, Pedi, Frank Jr.
• Granted Patent: US 7,316,821 B2
• Time in Patent Office: Days
• US Class Current: 424/471
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2072 characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms A61K9/0004, A61K9/0056, A61K9/0065 take precedence
• CPC Class Codes: A61K 9/2081 with microcapsules or coated microparticles according to A61K9/50
• CPC Class Codes: A61K 9/2095 Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61K 9/5089 Processes

Abstract

A stabilized solid cqntrolled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

Claims

1-38. -38. (Canceled)

39. A controlled release layered bead for inclusion in an oral controlled release pharmaceutical formulation comprising:

an inert bead coated with a therapeutically active agent,

a barrier layer over said bead coated with said therapeutically active agent, said barrier layer comprising hydroxypropylmethylcellulose,

a controlled release layer over said barrier layer, said controlled release layer derived from an aqueous dispersion of plasticized ethylcellulose in an amount sufficient to obtain a controlled release of said analgesic when said formulation is exposed to an environmental fluid,

said controlled release layered bead being cured to a temperature greater than the glass transition temperature of the plasticized ethylcellulose for at least about 24 hours.

40. The controlled release layered bead of claim 39, wherein said barrier layered bead is coated to a weight gain from about 2 to about 30% with said controlled release layer.

41. The controlled release layered bead of claim 39, wherein said therapeutically active agent is selected from the group consisting of anti-histamines, analgesics, non-steroidal anti-inflammatory agents, gastro-intestinals, anti-emetics, anti-epileptics, vasodilators, anti-tussive agents, expectorants, anti-asthmatics, hormones, diuretics, anti-hypotensives, anti-hypertensives, bronchodilators, antibiotics, antivirals, antihemorrhoidals, steroids, hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestant, laxatives, vitamins, and stimulants.

42. The controlled release layered bead of claim 39, wherein said therapeutically active agent is an opioid analgesic chosen from the group consisting of hydromorphone, oxycodone, dihydrocodone, codeins, dihydromorphone, morphine, buprenorphine, salts of any of the foregoing, and mixtures of any of the foregoing.

43. The controlled release layered bead of claim 39, further comprising a second barrier layer over said controlled release layer, said second barrier layer comprising hydroxypropylmethylcellulose.

44. The controlled release layered bead of claim 39, wherein said controlled release layer further comprises a release-modifying agent in an amount effective to modify the rate of release of said analgesic from said cured, coated bead.

45. The controlled release layered bead of claim 44, wherein said release-modifying agent is selected from the group consisting of a hydrophilic polymer, a semi-permeable polymer, an erosion-promoting polymer, an agent capable of making microporous lamina, a poreformer and mixtures of any of the foregoing.

46. The controlled release layered bead of claim 45, wherein said controlled release layer comprises from about 0.1% to about 70% of said release-modifying agent.

47. The controlled release layered bead of claim 46, wherein said release-modifying agent is selected from the group consisting of hydroxypropylmethylcellulose, lactose, metal stearates and mixtures of any of the foregoing.

48. The controlled release layered bead of claim 39, wherein a portion of the amount of said therapeutically active agent included in said bead is incorporated into an outer coating.

49. A method for preparing a controlled release layered bead for inclusion in an oral controlled release formulation of a therapeutically active agent, comprising:

coating a pharmaceutically acceptable inert bead with a therapeutically active agent;

thereafter coating said bead with a barrier layer comprising hydroxypropylmethylcellulose;

thereafter applying a controlled release layer onto said bead, said controlled release layer comprising a sufficient amount of a plasticized ethylcellulose to obtain a predetermined controlled release of said therapeutically active agent when said coated bead is exposed to an environmental fluid, said plasticized ethylcellulose being applied to said bead as an aqueous dispersion; and

curing said controlled release layered beads at a temperature greater than the glass transition temperature of the plasticized ethylcellulose for at least 24 hours.

50. The method of claim 49, further comprising coating said controlled release bead with an outer layer comprising said therapeutically active agent.

51. The method of claim 49, further comprising applying said controlled release layer onto said bead to a weight gain from about 2 to about 25%.

52. The method of claim 49, wherein said therapeutically active agent is selected from the group consisting of antihistamines, analgesics, non-steroidal anti-inflammatory agents, gastro-intestinals, anti-emetics, anti-epileptics, vasodilators, anti-tussive agents, expectorants, anti-asthmatics, hormones, diuretics, anti-hypotensives, anti-hypertensives, bronchodilators, antibiotics, antivirals, antihemorrhoidals, steroids, hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants, laxatives, vitamins and stimulants.

53. The method of claim 49, wherein said therapeutically active agent is an opioid analgesic chosen from the group consisting of hydromorphone, oxycodone, dihydrocodone, codeins, dihydromorphine, morphine buprenorphine, salts of any of the foregoing, and mixtures of any of the foregoing.

54. The method of claim 49, further comprising adding a release-modifying agent to said controlled release layer in an amount effective to modify the rate of release of said therapeutically active agent from said cured, coated bead.

55. The method of claim 54, wherein said release-modifying agent is selected from the group consisting of a hydrophilic polymer, a semi-permeable polymer, an erosion-promoting polymer, an agent capable of making microporous lamina, a pore-former, and mixtures of any of the foregoing.

56. The method of claim 55, wherein said controlled release layer comprises from about 0.1% to about 70% of said release-modifying agent.

57. The method of claim 56, wherein said controlled release layer comprises from about 0.1% to about 50% of said release-modifying agent.

58. The method of claim 57, wherein said controlled release layer comprises from about 0.1% to about 25% of said release-modifying agent.

59. The method of claim 54, wherein said release-modifying agent is selected from the group consisting of hydroxypropylmethylcellulose, lactose, metal stearates, and mixtures of any of the foregoing.

60. The method of claim 49, further comprising overcoating said controlled release bead with a second barrier layer comprising hydroxypropylmethylcellulose.

61. The method of claim 49, further comprising the step of oyercoating said controlled release bead with an outer layer comprising said therapeutically active agent.

62. The method of claim 61, wherein said outer layer comprises hydroxypropylmethylcellulose.

63. A controlled release layered bead for inclusion in a controlled release formulation, comprising

a pharmaceutically acceptable inert bead coated with a therapeutically active agent,

said bead coated with said therapeutically active agent being overcoated with a barrier layer comprising hydroxypropylmethylcellulose,

said barrier coated bead being coated with a controlled release layer derived from an aqueous dispersion of plasticized ethylcellulose in an amount sufficient to obtain a controlled release of said therapeutically active agent when said bead is exposed to a gastrointestinal fluid,

said coated bead being cured at a temperature greater than the glass transition temperature of the plasticized ethylcellulose for at least about 24 hours, to cause individual ethylcellulose particles in said coating to coalesce and to gradually slow the release of said analgesic when said bead is exposed to aqueous fluid, until an endpoint is reached at which said cured coated bead, when subjected to in-vitro dissolution, releases said therapeutically active agent in amounts which do not vary at any time point along the dissolution curve by more than about 20% of the total amount of therapeutically active agent released, when compared to the in-vitro dissolution of said coated bead prior to curing.

64. The controlled release layered bead of claim 63, wherein said cured, coated bead provides the same rate of release immediately after curing to said endpoint, and after subsequent exposure to accelerated storage conditions of one month at a temperature of 37°

C. and at a relative humidity of 80%.

65. The controlled release layered bead of claim 63, wherein said cured, coated bead provides the same rate of release immediately after curing to said endpoint, and after subsequent exposure to accelerated storage conditions of one month at a temperature of 40°

C. and at a relative humidity of 75%.

66. The controlled release layered bead of claim 63, wherein said controlled release layer is applied on said barrier coated bead to a weight gain from about 2% to about 25%.

67. The controlled release layered bead of claim 63, wherein said therapeutically active agent is selected from the group consisting of anti-histamines, analgesics, non-steroidal anti-inflammatory agents, gastro-intestinals, anti-emetics, anti-epileptics, vasodilators, anti-tussive agents, expectorants, anti-asthmatics, hormones, diuretics, anti-hypotensives, anti-hypertensives, bronchodilators, antibiotics, antivirals, antihemorrhoidals, steroids, hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants, laxatives, vitamins and stimulants.

68. The controlled release layered bead of claim 63, wherein said therapeutically active agent is an opioid analgesic chosen from the group consisting of hydromorphone, oxycodone, dihydrocodone, codeins, dihydromorphine, morphine, buprenorphine, salts of any of the foregoing, and mixtures of any of the foregoing.

69. The controlled release layered bead of claim 63, which includes said controlled release layer sufficient to obtain a controlled release of said therapeutically active agent when measured by the USP Paddle Method of U.S. Pharmacopeia XXII (1990) at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37°

C. from about 12.5% to about 42.5% (by wt) therapeutically active agent released after 1 hour, from about 25% to about 55% (by wt) therapeutically active agent released after 2 hours, from about 45% to about 75% (by wt) therapeutically active agent released after 4 hours and from about 55% to about 85% (by wt) therapeutically active agent released after 8 hours.

70. The controlled release layered bead of claim 63, wherein said controlled release layer further comprises a release-modifying agent in an amount effective to modify the rate of release of said analgesic from said cured, coated bead.

71. The controlled release layered bead of claim 70, wherein said release-modifying agent is selected from the group consisting of a hydrophilic polymer, a semi-permeable polymer, an erosion-promoting polymer, an agent capable of making microporous lamina, a poreformer and mixtures of any of the foregoing.

72. The controlled release layered bead of claim 63, further comprising a second barrier layer overcoated on said controlled release layer.

73. The controlled release layered bead of claim 72, wherein said second barrier layer comprises hydroxypropylmethylcellulose.

74. The controlled release layered bead of claim 73, further comprising an outer coating comprising a loading dose of said therapeutically active agent.